Drug Detail:Vandetanib (Vandetanib [ van-det-a-nib ])
Drug Class: EGFR inhibitors Multikinase inhibitors VEGF/VEGFR inhibitors
Drug Detail:Vandetanib (Vandetanib [ van-det-a-nib ])
Drug Class: EGFR inhibitors Multikinase inhibitors VEGF/VEGFR inhibitors
No information is available on the clinical use of vandetanib during breastfeeding. Because vandetanib is 90% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is 19 days and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during vandetanib therapy and for 4 months after the last dose.
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Relevant published information was not found as of the revision date.
Relevant published information was not found as of the revision date.
Vandetanib
443913-73-3
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.